BioGeneration Advisors

Prof. Dr. John Kastelein

Prof. Dr. John Kastelein is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam with a research interest in ethiology, diagnosis, prevention and treatment of hypertriglyceridaemia, hypercholesteroleamia and low HDL cholesterol. Prof. Kastelein was one of the founders of Amsterdam Molecular Therapeutics Inc. (AMT), a gene therapy company. Recently, Prof. Kastelein also founded Dezima Pharma, a pharmaceutical company that develops assets for the treatment of dyslipidemia. Prof. Kastelein is advisor to pharmaceutical and biotech companies developing cardiovascular disease drugs and principal investigator and advisor to many of the studies trialing new anti-dyslipidemia compounds. Prof. Kastelein is member of several national and international medicine, atherosclerosis and cardiology societies aiming to study, prevent and treat cardiovascular diseases. Prof. Kastelein received the first Lifetime Achievement Award of the Dutch Heart Foundation in 2010 as well as the ZonMW Parel price and the Anitschkov Price from the European Atherosclerosis Society for the best atherosclerosis research in Europe in June 2014. He also was a recipient of the Huibregtsenprice 2014 for the best academic researcher in the Netherlands. Prof. Kastelein has published over 740 research papers in peer reviewed journals.


Prof. Dr. Emile Voest

Emile Voest is professor of Medical Oncology and serves as Medical Director on the executive board of the Netherlands Cancer Institute in Amsterdam. In addition he is involved in several other initiatives: he is board member of the Center for Personalized Cancer Treatment (a national program involving academic cancer centers and teaching hospitals), medical director on the board of the HUB Foundation for Organoid Technology and Stemcell technology, chair of ASCO’s Cancer Research Committee and serves on ESMO’s executive board. His translational research has focused on improving systemic treatment for patients with cancer. This includes the clinical development of targeted agents, discovery and validation of biomarkers with emphasis on genetics and tumor organoids, and identification of new targets of treatment to overcome chemoresistance. Dr Voest was registered as a medical doctor in 1985. He became board certified as an internist July 1993, and as a medical oncologist in January 1995. He completed his PhD program on the enhancement of the efficacy of anthracyclines by modulation of iron metabolism in tumor cells June 1993 (cum laude). In 1994 and 1995 he was a postdoctoral fellow of the Dutch Cancer Society. He was a postdoctoral fellow in the laboratory of Dr. Judah Folkman, Children's Hospital, Harvard Medical School, Boston. Thereafter he worked at the Netherlands Cancer Institute in Amsterdam on high dose chemotherapy. November 1999 he became a full professor in Medical Oncology at the University of Utrecht. He has several patents to his name in the field of angiogenesis and biomarkers. In 2011, he spend a 6 months sabbatical at UCSD on bioinformatics and systems biology. He co-authored over 200 manuscripts that together have been cited almost 7,000 times. Dr Voest currently serves as one of the Team Leaders in the Stand up to Cancer International Translational Research Grant “Prospective Use of DNA-guided Personalized Cancer Treatment”.


Dr. Koen Wiedhaup

As a senior executive with extensive international expertise in the pharmaceutical and biotech industry, Koen Wiedhaup is actively involved in the creation of new life sciences companies. Over the last fifteen years, he has worked together with UK and USA based venture capital firms and has served as a board member of governmental foundations, such as the Netherlands Genomics Initiative and Health Valley Netherlands. He is a member of the Supervisory Board of the BioGeneration Ventures Fund I, and of the Investment Committee of PPM Oost, a venture capital company managing regional and national government funding in the Netherlands. Wiedhaup has been, or still is, a member of supervisory and advisory boards of thirteen life sciences companies in the USA and Europe, several of which have successfully completed an IPO. Over the last decade, he has been active as vice-president of the Supervisory Board of the University Medical Center in Maastricht (AZM) and as member of the Supervisory Board of the Canisius-Wilhelmina Hospital in Nijmegen. He is a member of the Ambassadors Network of the Dutch University of Twente. From 1977 to 1994, Wiedhaup has been board member and managing director for Global R&D of the former pharmaceutical company Organon, and subsequently Group Director of Akzo-Nobel Pharma, responsible for R&D and strategic planning until 2000. Koen Wiedhaup obtained his PhD at the University of Amsterdam. Previous to joining Organon, he held positions at the San Francisco Medical Center of the University of California, at Stanford University, CA, and with Unilever in Rotterdam and London.


Roger Ulrich Ph. D. 

Roger UlrichDr. Roger Ulrich is an entrepreneur and biotech executive with more than 30 years of operational and administrative experience in the pharmaceutical industry. He is a member of the Board of Directors for Acerta Pharma BV and served as the company’s Chief Scientific Officer until the majority acquisition by AstraZeneca in 2016.  He is also on the Board of Directors for Remedy Pharmaceuticals, is a Senior Advisor to Frazier Healthcare Partners, and serves as a scientific advisor to several small pharma companies. Prior to Acerta, he was Founder and Chief Development Officer at Calistoga Pharmaceuticals Inc., where he led the development of CAL-101 (GS-1101, idelalisib) now approved as Zydelig® for the treatment of patients with hematologic malignancies. Calistoga was acquired by Gilead Sciences in 2011. Prior to Calistoga, Dr. Ulrich was Senior Scientific Director with Merck Research Laboratories/Rosetta Inpharmatics, Director of Regulatory Toxicology, Safety Pharmacology, Genetic Toxicology, Cellular and Molecular Toxicology, Microscopy and Microanalysis at Abbott Laboratories, and a Senior Scientist with The Upjohn Company and Pharmacia & Upjohn Inc. Prior to his pharmaceutical industry career he held positions at West Virginia University, Michigan State University, and at Argonne National Laboratories. Dr. Ulrich holds several patents and has authored more than 125 publications. He received his Bachelor of Arts degree in Biology/Chemistry and his Masters of Arts in Biomedical Sciences from Western Michigan University. He received his doctorate in Cellular and Molecular Biology from West Virginia University, and is a Fellow of the Academy of Toxicological Sciences.

Desktop versie